Vimarsana
Biggest News Aggregation in the World

Microsatellite Instability News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Microsatellite Instability. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Microsatellite Instability Today - Breaking & Trending Today

European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite... - Vimarsana News

European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...

Application based on results from the CheckMate -8HW study, in which Opdivo plus Yervoy demonstrated statistically significant and clinically meaningful improvement in progression-free survival...

French Cohort Shows Good Prognosis of MSI Colorectal Cancer - Vimarsana News

French Cohort Shows Good Prognosis of MSI Colorectal Cancer

Nonmetastatic microsatellite instability colorectal cancers nevertheless entailed a high risk for recurrence in stage III, especially when not treated with adjuvant chemotherapy.

XRCC1 shows potential as a prognostic and immunological pan-cancer biomarker - Vimarsana News

XRCC1 shows potential as a prognostic and immunological pan-cancer biomarker

A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 1, entitled, "XRCC1: a potential prognostic and immunological biomarker in LGG based on systematic pan-cancer analysis."

Immunotherapy Combo Wins Big on PFS in First-Line Mets CRC - Vimarsana News

Immunotherapy Combo Wins Big on PFS in First-Line Mets CRC

First-line nivolumab plus ipilimumab led to significantly better 2-year PFS in metastatic CRC than chemotherapy as well as pembrolizumab monotherapy.

Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary... - Vimarsana News

Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary...

Opdivo plus Yervoy demonstrates statistically significant and clinically meaningful improvement in progression-free survival compared to investigator’s choice of chemotherapy Combination of...